YK-11 Mechanism of Action — Research Reference
YK-11 is extensively studied for its distinctive dual mechanism of action, functioning both as a steroidal selective androgen receptor modulator (SARM) and a modulator of the myostatin pathway. Research primarily focuses on its interactions with androgen receptors and its potential to influence myostatin-mediated signaling, positioning it as a compound of significant interest in understanding muscle tissue biology at a molecular level.
This reference provides an in-depth exploration of the proposed YK-11 mechanism of action, drawing from numerous peer-reviewed publications indexed in databases like PubMed and observations from several registered studies on ClinicalTrials.gov. The information presented herein is intended strictly for research purposes, facilitating a deeper understanding of YK-11’s molecular interactions, cellular effects, and the broader implications for advanced biological research.
Understanding YK-11: Classification and Research Context
YK-11 is a compound that has garnered significant attention within neuropharmacology and performance research, primarily due to its unique dual classification. It is widely categorized as a Selective Androgen Receptor Modulator (SARM), a class of experimental compounds designed to exhibit tissue-selective androgenic activity. Unlike traditional anabolic-androgenic steroids (AAS), SARMs aim to preferentially stimulate androgen receptors (ARs) in specific tissues, such as skeletal muscle and bone, while minimizing undesirable androgenic effects in other tissues like the prostate or sebaceous glands. This selectivity is a key area of ongoing research for SARMs, as it suggests a potentially more favorable risk-benefit profile in investigative settings compared to non-selective agonists. The study of YK-11 within this framework focuses on understanding the molecular mechanisms underpinning this purported tissue specificity and efficacy in promoting anabolic effects.
Beyond its SARM classification, YK-11 is also recognized as a myostatin modulator. Myostatin, a protein belonging to the transforming growth factor-beta (TGF-β) superfamily, acts as a negative regulator of muscle growth. By inhibiting myostatin activity, YK-11 is hypothesized to remove this natural ‘brake’ on muscle development, thereby allowing for enhanced muscle anabolism. This dual mechanism of action—AR agonism coupled with myostatin modulation—distinguishes YK-11 from other SARMs and traditional anabolic agents, positioning it as a particularly intriguing subject for mechanistic research. Investigating how these two distinct pathways converge or interact to produce observed outcomes in research models is a critical component of current YK-11 studies.
The scientific community’s interest in YK-11 is evidenced by numerous publications indexed in PubMed, detailing various aspects of its chemical properties, biological activity in cell cultures, and effects in preclinical animal models. These studies span a range of disciplines, from synthetic organic chemistry exploring its molecular design to molecular biology elucidating its interaction with cellular receptors and signaling pathways. Furthermore, the presence of several registered studies on ClinicalTrials.gov, although often exploring its potential in broader physiological contexts, underscores the ongoing research efforts to characterize its mechanism of action and its implications for understanding fundamental biological processes. It is crucial to note that all current research endeavors strictly adhere to the ‘research-use-only’ framework, focusing on understanding its biochemical and physiological impacts in controlled laboratory environments.
Research into YK-11 contributes to a broader understanding of muscle physiology, AR signaling, and myostatin regulation. By dissecting the precise ways in which YK-11 exerts its effects, researchers aim to uncover novel therapeutic targets or pathways that could be modulated for conditions involving muscle wasting or impaired anabolism. The complexity of YK-11’s mechanism makes it an excellent probe for investigating the intricate crosstalk between endocrine signaling and growth factor pathways. For more details on ongoing studies and the current landscape of YK-11 research, interested parties can explore YK-11 research overviews provided by Royal Peptide Labs.
Molecular Structure and Androgen Receptor Binding Profile
YK-11, chemically identified as (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,9,20-triene, possesses a unique steroidal backbone that is crucial for its interaction with biological targets. Despite often being grouped with non-steroidal SARMs due to its functional properties, its core structure is undeniably steroidal, derived from 19-norprogesterone. This specific structural configuration, including its characteristic 17α-methoxymethylene group and conjugated triene system, plays a pivotal role in dictating its pharmacological profile. The deviations from classical testosterone or dihydrotestosterone (DHT) structures are hypothesized to confer its selectivity, potentially guiding its interaction with the androgen receptor (AR) in a manner that differs from full, non-selective agonists.
The interaction of YK-11 with the androgen receptor (AR) is a central aspect of its mechanism of action. The AR is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. Upon binding a suitable ligand, the AR undergoes a conformational change, disassociates from heat shock proteins, translocates to the nucleus, dimerizes, and binds to specific DNA sequences known as androgen response elements (AREs) to modulate gene transcription. Research into YK-11’s binding profile typically involves *in vitro* competitive binding assays, where its affinity for the AR is compared against known endogenous androgens like testosterone or DHT. These studies aim to quantify its relative binding affinity (RBA) and determine if it acts as a full or partial agonist in different cellular contexts, which is critical for understanding its tissue selectivity.
Computational modeling, including molecular docking and molecular dynamics simulations, further complements experimental data by providing insights into the precise atomic interactions between YK-11 and the ligand-binding domain (LBD) of the AR. Such *in silico* approaches allow researchers to predict how YK-11’s unique structural features influence its orientation within the AR binding pocket, potentially explaining its selective agonistic properties. For instance, subtle differences in hydrogen bonding networks or hydrophobic interactions compared to full agonists could lead to distinct receptor conformations, thereby dictating the recruitment of co-activator or co-repressor proteins, and ultimately influencing the transcriptional outcome in a tissue-specific manner. This intricate interplay at the molecular level is fundamental to its purported SARM activity.
Furthermore, the stability and purity of YK-11 are paramount for accurate and reproducible research outcomes. The specific molecular structure must be consistently verified to ensure that experimental results reflect the activity of the intended compound and not impurities or degradation products. Advanced analytical techniques such as High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR) spectroscopy are routinely employed in research settings to confirm the identity and purity of YK-11 samples. Ensuring the integrity of the research compound is a foundational step for any mechanistic investigation into its AR binding and downstream effects, underlining the importance of quality control in experimental pharmacology. Information on such verification processes can be found on quality testing pages.
The Androgen Receptor Agonism Pathway in Research Models
The primary mechanism by which YK-11 is thought to exert its SARM-like effects involves the agonistic modulation of the androgen receptor (AR) pathway. In research models, this begins with the binding of YK-11 to the intracellular AR. Upon ligand binding, the AR undergoes a conformational change, leading to its dissociation from chaperone proteins like heat shock protein 90 (HSP90) in the cytoplasm. This dissociation facilitates the translocation of the liganded AR into the cell nucleus, a critical step for its function as a transcription factor. Inside the nucleus, the AR homodimerizes, forming a complex that recognizes and binds to specific DNA sequences known as androgen response elements (AREs) located in the promoter regions of target genes.
Once bound to AREs, the YK-11-AR complex recruits various co-activator proteins, such as steroid receptor co-activator 1 (SRC-1) or glucocorticoid receptor interacting protein 1 (GRIP1), leading to the initiation of gene transcription. The specific set of co-activators recruited, and the efficiency of their recruitment, can vary depending on the conformation induced by the ligand. It is hypothesized that YK-11, as a selective modulator, might induce a unique AR conformation that preferentially recruits co-activators leading to anabolic gene expression in muscle and bone tissues, while perhaps discouraging the recruitment of co-activators associated with adverse effects in other androgen-sensitive tissues like the prostate. Research methodologies such as reporter gene assays, where a gene encoding a detectable protein (e.g., luciferase) is placed under the control of an ARE, are commonly employed to quantify the transcriptional activity of YK-11 in various cell lines expressing the AR.
Further investigation into the AR agonism pathway involves analyzing the downstream gene expression changes induced by YK-11 in relevant research models. Techniques like quantitative real-time PCR (RT-qPCR) and Western blotting are used to measure the levels of AR target genes and proteins. Genes involved in muscle protein synthesis, such as those encoding myosin heavy chain, actin, and various growth factors, are often monitored. For instance, an increase in the expression of MyoD, myogenin, or MRF4, which are muscle regulatory factors, could indicate enhanced myogenesis. Conversely, changes in the expression of prostate-specific antigen (PSA) in prostate cell lines or other markers of androgenicity in non-target tissues are carefully monitored to assess the selectivity profile of YK-11. These studies aim to delineate the precise transcriptional fingerprint induced by YK-11, distinguishing it from non-selective androgens.
The tissue-specific effects attributed to YK-11 are a cornerstone of SARM research. While it is expected to promote anabolic signaling in skeletal muscle, the degree to which it avoids stimulating AR in other tissues remains a critical area of investigation. This tissue selectivity is not solely determined by AR binding affinity but also by the distribution of ARs in different tissues, the local metabolic conversion of androgens, and the specific complement of co-regulatory proteins available in each cell type. Research models, ranging from *in vitro* co-culture systems to *in vivo* rodent models, are employed to map this intricate network of interactions. For researchers interested in the broader class of compounds that modulate these fundamental pathways, understanding the mechanisms of research peptides can offer valuable comparative insights.
Myostatin Pathway Modulation: A Distinct Mechanism
Beyond its activity as an androgen receptor agonist, YK-11 presents a fascinating and distinct mechanism of action involving the modulation of the myostatin pathway. Myostatin, also known as Growth Differentiation Factor 8 (GDF-8), is a potent negative regulator of skeletal muscle growth and differentiation. It is primarily expressed in skeletal muscle and acts in an autocrine and paracrine fashion, binding to the activin type II receptors (ActRIIA/B) on muscle cell surfaces. This binding initiates a signaling cascade, typically involving the phosphorylation of Smad2 and Smad3 proteins, which then complex with Smad4 and translocate to the nucleus to regulate the transcription of genes that inhibit muscle growth and promote muscle atrophy. Essentially, myostatin puts a natural brake on how much muscle an organism can develop.
The hypothesis is that YK-11 can counteract the inhibitory effects of myostatin, thereby promoting an environment conducive to increased muscle mass and strength in research models. One proposed mechanism for this myostatin modulation is through the upregulation of follistatin. Follistatin is a naturally occurring glycoprotein that acts as a potent myostatin antagonist by directly binding to myostatin and preventing its interaction with its receptors. By increasing follistatin levels, YK-11 could effectively sequester myostatin, preventing it from activating its catabolic signaling pathway. Research studies often use RT-qPCR to quantify follistatin mRNA expression and ELISA to measure follistatin protein levels in response to YK-11 treatment in muscle cell cultures or animal models, looking for a direct correlation.
Another potential mechanism, which is less thoroughly elucidated but subject to ongoing investigation, involves direct or indirect interference with the myostatin signaling cascade downstream of receptor binding. This could include modulation of the Smad pathway, influencing the phosphorylation status or nuclear translocation of Smad proteins, or altering the expression of other factors involved in muscle growth and repair. By inhibiting the myostatin pathway, YK-11 is thought to shift the balance towards anabolism, reducing protein degradation and enhancing protein synthesis, ultimately leading to hypertrophy and hyperplasia of muscle fibers in research settings. This dual action, combining AR agonism with myostatin inhibition, positions YK-11 as a unique compound for studying muscle growth regulation.
Research into the myostatin pathway modulation by YK-11 often involves specific experimental readouts to assess its impact. These include measurements of muscle fiber size, satellite cell proliferation and differentiation, and expression of key muscle growth markers in *in vitro* and *in vivo* models. Furthermore, researchers might investigate the myostatin signaling components directly through techniques such as Western blotting for phosphorylated Smad2/3 or electrophoretic mobility shift assays (EMSAs) to assess Smad complex DNA binding. The precise interplay between YK-11, myostatin, and follistatin is complex and warrants further in-depth investigation to fully characterize this distinct mechanistic aspect.
Key Components and Readouts in Myostatin Pathway Research
- Myostatin (GDF-8): The primary target, a negative regulator of muscle growth.
- Activin Type II Receptors (ActRIIA/B): Receptors to which myostatin binds on muscle cell surfaces.
- Smad2/3 and Smad4: Intracellular signaling proteins that transduce the myostatin signal.
- Follistatin: A glycoprotein antagonist that binds and neutralizes myostatin.
- Research Readouts:
- mRNA/protein levels of myostatin, follistatin, and related signaling molecules.
- Phosphorylation status of Smad2/3 (indicator of pathway activation).
- Muscle cell proliferation, differentiation, and hypertrophy in culture.
- Muscle mass, fiber type, and cross-sectional area in animal models.
Investigating Downstream Signaling and Gene Expression Effects
The dual mechanisms of YK-11, involving both androgen receptor (AR) agonism and myostatin pathway modulation, converge to elicit a complex array of downstream signaling events and changes in gene expression within target cells. A primary focus of research in this area is to understand how these two pathways integrate and contribute to the observed anabolic effects, particularly in skeletal muscle. Following AR activation and myostatin inhibition (potentially via follistatin upregulation), a cascade of intracellular signaling pathways is affected, which ultimately influences protein synthesis, protein degradation, and cellular growth. Key pathways often investigated include the Akt/mTOR (mammalian target of rapamycin) pathway, which is a central regulator of cell growth, proliferation, and protein synthesis. Increased phosphorylation of Akt and downstream targets like S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) are common indicators of enhanced anabolic signaling.
At the gene expression level, comprehensive transcriptomic analyses using techniques such as RNA sequencing (RNA-seq) or microarray technology are employed to identify the global changes induced by YK-11. These studies aim to generate a detailed molecular signature, revealing upregulated genes associated with muscle protein synthesis, satellite cell activation, and myogenesis, and downregulated genes related to muscle atrophy or catabolism. Specific gene targets often examined include those encoding structural muscle proteins (e.g., actins, myosins), muscle-specific transcription factors (e.g., MyoD, myogenin, MRF4), and factors involved in cellular metabolism and energy production. Furthermore, research explores how YK-11 might modulate the expression of genes involved in extracellular matrix remodeling, satellite cell niche regulation, and angiogenesis, all of which are critical for muscle tissue development and repair.
The interplay between AR signaling and myostatin pathways is crucial. AR activation typically leads to increased expression of myogenic regulatory factors and insulin-like growth factor 1 (IGF-1), both of which are potent promoters of muscle growth. Simultaneously, myostatin inhibition releases the negative brake on these processes. Researchers investigate whether YK-11 amplifies these effects synergistically or acts independently through each pathway to achieve its outcomes. For example, some studies explore if AR activation by YK-11 directly influences follistatin expression, creating a feedback loop that enhances myostatin inhibition. This intricate crosstalk between steroid hormone signaling and growth factor pathways presents a rich area for molecular investigation. Epigenetic modifications, such as DNA methylation and histone acetylation, are also emerging as areas of interest, as they can profoundly influence gene expression patterns and may represent a long-term mechanism by which YK-11 exerts its effects.
Understanding the full spectrum of downstream signaling and gene expression changes is vital for characterizing the complete mechanism of action of YK-11. This information is not only critical for basic research into muscle physiology but also for comparative studies with other anabolic agents or myostatin inhibitors. By precisely mapping the molecular cascades, researchers can identify key nodes that are uniquely affected by YK-11, potentially distinguishing its effects from those of other compounds and providing insights into its distinctive profile. The table below summarizes some key genes and pathways frequently investigated in research pertaining to YK-11’s downstream effects.
Key Genes and Pathways Regulated by YK-11 in Research Models
| Pathway/Category | Key Genes/Proteins (Examples) | Observed Effects (in Research) | Measurement Techniques |
|---|---|---|---|
| Androgen Receptor Signaling | AR, PSA (in prostate cells), MyoD, Myogenin, IGF-1 | Increased anabolic gene transcription, muscle regulatory factor activation | RT-qPCR, Western Blot, Reporter Gene Assays |
| Myostatin Pathway | Myostatin (GDF-8), Follistatin, Smad2/3 (phosphorylation) | Myostatin inhibition, follistatin upregulation, reduced Smad activation | RT-qPCR, Western Blot (phospho-Smad), ELISA |
| Protein Synthesis/Anabolism | Akt, mTOR, S6K1, 4E-BP1, MyHC (Myosin Heavy Chain), Actin | Enhanced protein synthesis, increased phosphorylation of anabolic kinases | Western Blot, RT-qPCR, Immunofluorescence |
| Muscle Growth & Differentiation | Pax7 (Satellite Cell Marker), MyoD, Myogenin | Promoted myogenesis, satellite cell proliferation and differentiation | Immunohistochemistry, Flow Cytometry, RT-qPCR |
| Protein Degradation | Atrogin-1, MuRF1 (E3 ligases) | Potential downregulation (reduced catabolism) | RT-qPCR, Western Blot |
Comparative Analysis with Other Research Compounds
A critical aspect of understanding YK-11’s mechanism of action involves its comparative analysis with other research compounds, particularly other Selective Androgen Receptor Modulators (SARMs), traditional anabolic-androgenic steroids (AAS), and dedicated myostatin inhibitors. This comparative framework allows researchers to delineate the unique profile of YK-11, assessing its relative potency, selectivity, and the specific contribution of its dual mechanisms to observed outcomes in various research models. For instance, when compared to first-generation SARMs like Ostarine (MK-2866) or LGD-4033, YK-11’s steroidal structure and purported myostatin inhibition represent significant mechanistic distinctions. While most SARMs aim for tissue-selective AR agonism, YK-11’s additional pathway modulation suggests potentially different magnitudes or types of anabolic responses, particularly concerning muscle growth beyond what AR agonism alone might achieve.
Compared to traditional anabolic-androgenic steroids, such as testosterone or dihydrotestosterone, YK-11 is hypothesized to offer a more selective anabolic profile. AAS compounds are known for their potent AR agonism across a wide range of tissues, leading to a spectrum of androgenic and anabolic effects. Research into YK-11, like other SARMs, seeks to dissociate the desirable anabolic effects in muscle and bone from undesirable androgenic effects in prostate, hair follicles, and sebaceous glands, as well as minimizing the suppression of endogenous hormone production. By studying YK-11’s binding kinetics, co-regulator recruitment, and transcriptional fingerprint in different cell lines (e.g., muscle, bone, prostate), researchers can empirically evaluate the extent of its tissue selectivity compared to non-selective AAS. This involves meticulous measurement of both anabolic markers and potential androgenic side markers in controlled *in vitro* and *in vivo* experiments.
Furthermore, YK-11’s classification as a myostatin modulator necessitates its comparison with compounds specifically designed to inhibit myostatin. These include natural inhibitors like follistatin, as well as experimental anti-myostatin antibodies or ActRIIB antagonists. Research aims to determine if YK-11’s myostatin modulation, possibly via follistatin upregulation, achieves a similar degree of inhibition as these dedicated agents. The distinctiveness of YK-11 lies in its purported ability to engage both AR agonism and myostatin inhibition simultaneously. Comparative studies might investigate whether the combined effect of YK-11 is synergistic, additive, or simply a dominant effect from one pathway. For example, experiments could involve treating muscle cells with YK-11, a pure SARM, or a pure myostatin inhibitor, and then measuring muscle protein synthesis, satellite cell proliferation, and gene
Frequently Asked Questions
What is the primary classification of YK-11 in research?
YK-11 is primarily classified in research as a steroidal selective androgen receptor modulator (SARM) and a myostatin modulator, indicating its dual mechanistic properties under investigation.
How does YK-11 interact with androgen receptors in research models?
In research models, YK-11 is studied as a partial agonist of the androgen receptor, meaning it can bind to the receptor and induce a conformational change leading to altered gene transcription, though potentially with tissue selectivity or a different transcriptional profile compared to full agonists.
What role does myostatin play in YK-11’s proposed mechanism of action?
Myostatin is a negative regulator of muscle growth; YK-11’s proposed mechanism includes modulating the myostatin pathway, potentially by increasing follistatin expression which in turn inhibits myostatin activity, thereby influencing protein synthesis and degradation pathways in research models.
Is YK-11 considered a conventional SARM based on its structure?
No, YK-11 is structurally distinct from many non-steroidal SARMs due to its steroidal backbone, which may influence its receptor binding kinetics, metabolic profile, and downstream signaling pathways, making it a unique subject of research.
What cellular signaling pathways are investigated in relation to YK-11’s action?
Research on YK-11’s mechanism often investigates its influence on cellular signaling pathways such as MAPK (ERK, p38), Akt/mTOR, and pathways related to satellite cell activation, which are critical regulators of muscle protein synthesis and differentiation.
How does YK-11’s mechanism compare to traditional anabolic androgenic steroids (AAS) in research?
In research, YK-11’s mechanism is differentiated from traditional AAS by its proposed selective androgen receptor modulation and its myostatin inhibition component. While AAS exert broad androgenic effects, YK-11 is studied for potentially more targeted modulation in research models, though its steroidal nature may present some similarities in metabolism or receptor interactions to certain AAS.
What research methodologies are typically used to study YK-11’s mechanism of action?
Common methodologies include in vitro cell-based assays (e.g., reporter gene assays, Western blotting, immunofluorescence), gene expression analysis (RT-qPCR, RNA-seq), and in vivo studies using animal models to assess tissue-specific effects, metabolic alterations, and functional changes.
What are the primary research questions driving current YK-11 studies regarding its mechanism?
Current research questions often revolve around fully elucidating the precise molecular interactions, confirming the extent of its myostatin modulation, understanding its tissue selectivity and gene expression profile, identifying potential metabolites and their activities, and investigating its long-term cellular effects in controlled research environments.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.